Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy Invited Commentary Invited Commentary Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy Viridiana Kocaba, MD, PhD; Silke Oellerich, PhD; Gerrit R. J. Melles, MD, PhD Over the past decade, Descemet membrane endothelial 60 years included in the derivation cohort (mean age, 67 years; keratoplasty (DMEK) has become the standard for the treat- range, 57-77 years). In addition to including demographic, ment of endothelial diseases, with Fuchs endothelial corneal subjective, and optical parameters, a comprehensive model dystrophy (FECD) being the most common indication. Des- for predicting DMEK outcome in eyes with FECD should take cemet membrane endothe- the pathogenesis of the disease into account, as disease sever- ity may play an important role in predicting postoperative lial keratoplasty in eyes with Related article FECD usually results in suc- outcomes. cessful clinical outcomes with low postoperative complica- Over the past 2 decades, there have been substantial ad- tion rates. Because of the fast and reliable visual rehabilita- vances in understanding FECD pathogenesis. Fuchs endothe- tion after DMEK, the visual threshold for undergoing corneal lial corneal dystrophy is defined as a complex epigenetic dis-
JAMA Ophthalmology – American Medical Association
Published: Apr 18, 2021
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera